Quelimmune (SCD-Pediatric)
Pediatric Acute Kidney Injury (AKI) with Sepsis/Septic Condition
ApprovedCommercial (Launched July 2024)
Key Facts
Indication
Pediatric Acute Kidney Injury (AKI) with Sepsis/Septic Condition
Phase
Approved
Status
Commercial (Launched July 2024)
Company
About SeaStar Medical
SeaStar Medical is executing a mission to transform outcomes for critically ill patients suffering from hyperinflammatory conditions like cytokine storm. Its key achievement is the FDA approval and commercial launch of Quelimmune, a pediatric therapy approved under a Humanitarian Device Exemption. The company's strategy leverages its proprietary SCD platform across multiple high-need adult critical care indications, supported by FDA Breakthrough Device Designations, aiming to address a multi-billion dollar market with a disease-modifying therapeutic approach.
View full company profile